Juan Garza
Rheumatology · Jbsa Lackland, TXNPI 1821072323
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $520 and has fallen 96.2% since, to $20 in 2025. That places this record below the midpoint for rheumatology clinicians in TX, where the typical reported total is $3,779.
Across 65 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$266
- Lilly USA, LLC$205
- Rigel Pharmaceuticals, Inc.$148
- Johnson & Johnson$96
- CTI Biopharma Corp.$90
- Boehringer Ingelheim$87
- plus $548 from 12 others
Across 13 payments — averaging $40,078 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$521K
- Pfizer$192
What the payments were for
- Food & beverage$1,440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 7 | $266 |
| Lilly USA, LLC | 11 | $205 |
| Rigel Pharmaceuticals, Inc. | 5 | $148 |
| Johnson & Johnson | 5 | $96 |
| CTI Biopharma Corp. | 4 | $90 |
| Boehringer Ingelheim | 5 | $87 |
| Morphosys, US Inc. | 4 | $85 |
| Puma Biotechnology, Inc. | 4 | $76 |
| Taiho Oncology, Inc. | 4 | $74 |
| Servier Pharmaceuticals LLC | 3 | $62 |
| Bayer | 3 | $59 |
| Karyopharm Therapeutics Inc. | 3 | $52 |
| Acceleron Pharma, Inc. | 2 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Myovant Sciences Inc. | 1 | $22 |
| Novo Nordisk | 1 | $14 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$125
How this compares
$1,440 in reported general payments places this provider in the 30th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Jbsa Lackland
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.